Ferucarbotran (Resovist): A new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: Properties, clinical development, and applications

European Radiology

Volumn 13, Issue 6, 2003, Pages 1266-1276

  Reimer, Peter ^a   Balzer, Thomas ^b  

^a STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Dynamic MRI; Ferucarbotran; Lesion characterization; Liver; Low field high field; MRA; SPIO; Time window

Indexed keywords

CONTRAST MEDIUM; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; GADOBENATE DIMEGLUMINE; GADOLINIUM CHELATE; MANGAFODIPIR; SH U 55A; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANGIOGRAPHY; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; HEPATOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; INTERVENTIONAL RADIOLOGY; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; LOW BACK PAIN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SURGICAL PATIENT;

EID: 0038756705     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-002-1721-7     Document Type: Review

References (48)

1. Reimer P, Tombach B (1998) Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Eur Radiol 8:1198-1204
2. Wang YX, Hussain SM, Krestin GP (2001) Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11:2319-2331
3. Weissleder R (1994) Liver MR imaging with iron oxides: toward consensus and clinical practice. Radiology 193:593-595
4. Reimer P, Rummeny EJ, Daldrup HE et al. (1995) Clinical results with Resovist: a phase 2 clinical trial. Radiology 195:489-496
5. Hamm B, Staks T, Taupitz M et al. (1994) Contrast enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J Magn Reson Imaging 4:659-668
6. Josephson L, Lewis J, Jacobs P, Hahn PF, Stark DD (1988) The effects of iron oxides on proton relaxivity. Magn Reson Imaging 6:647-653
7. McLachlan SJ, Morris MR, Lucas MA et al. (1994) Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 4:301-307
8. Weissleder R, Stark DD, Engelstad BL et al. (1989) Superparamagnetic iron oxide: pharmacokinetics and toxicity. Am J Roentgenol 152:167-173
9. Hahn PF, Stark DD, Elizondo G, Weissleder R, Saini S, Ferrucci JT (1990) Clinical application of superparamagnetic iron oxide to MR imaging of tissue perfusion in vascular liver tumors. Radiology 174:361-366
10. Stark DD, Weissleder R, Elizondo G et al. (1988) Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 168:297-301
11. Hamm B, Staks T, Taupitz M (1994) A new superparamagnetic iron oxide contrast agent for magnetic resonance imaging. Invest Radiol 29:S87-S89
12. Tavill AS, Bacon BR (1986) Hemochromatosis: How much is too much. Hepatology 6:142-145
13. Bassett ML, Halliday JW, Powell LW (1986) Value of hepatic iron measurments in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 6:24-29
14. Reimer P, Marx C, Rummeny EJ et al. (1997) SPIO-enhanced 2D-TOF MR-angiography of the portal venous system: results of an intraindividual comparison. J Magn Reson Imaging 7:945-949
15. Kopp AF, Laniado M, Dammann F et al. (1997) MR imaging of the liver with Resovist: safety, efficacy and pharmacodynamic properties. Radiology 204:749-756
16. Shamsi K, Balzer T, Saini S et al. (1996) Evaluation of efficacy of Resovist in three doses for MRI of the liver: a blinded reader study [abstract]. Am J Roentgenol:43
17. DeLand FH, North WA (1968) Relationship between liver size and body size. Radiology 91:1195-1198
18. Kehagias DT, Gouliamos AD, Smyrniotis V, Vlahos LJ (2001) Diagnostic efficacy and safety of MRI of the liver with superparamagnetic iron oxide particles (SH U 555 A). J Magn Reson Imaging 14:595-601
19. Ba-Ssalamah A, Heinz-Peer G, Schima W et al. (2000) Detection of focal hepatic lesions: comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP. J Magn Reson Imaging 11:665-672
20. Reimer P, Jahnke N, Fiebich M et al. (2000) Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology 217:152-158
21. Zheng WW, Zhou KR, Chen ZW, Shen JZ, Chen CZ, Zhang SJ (2002) Characterization of focal hepatic lesions with SPIO-enhanced MRI. World J Gastroenterol 8:82-86
22. Grandin C, van Beers BE, Robert A, Gigot JF, Geubel A, Pringot J (1995) Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration. J Comput Assist Tomogr 19:412-418
23. Saini S, Edelman RR, Sharma P et al. (1995) Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). Am J Roentgenol 164:1147-1152
24. Van Gansbeke D, Metens TM, Matos C et al. (1997) Effects of AMI-25 on liver vessels and tumors on T1-weighted turbo-field-echo images: implications for tumor characterization. J Magn Reson Imaging 7:482-489
25. Vogl TJ, Hammerstingl R, Schwarz W et al. (1996) Magnetic resonance imaging of focal liver lesions: comparison of the superparamagnetic iron oxide Resovist versus gadolinium-DTPA in the same patient. Invest Radiol 31:696-708
26. Yamamoto H, Yamashita Y, Yoshimatsu S, Baba Y, Takahashi M (1995) MR enhancement of hepatoma by superparamagnetic iron oxide (SPIO) particles. J Comput Assist Tomogr 19:665-667
27. Lim JH, Choi D, Cho SK et al. (2001) Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology 220:669-676
28. Reimer P, Müller M, Marx C et al. (1998) T1-effects of a bolus-injectable SPIO "SH U 555 A": dependency on field strength, plasma concentration, and preliminary clinical experience with dynamic T1-weighted MRI. Radiology 209:831-836
29. Grangier C, Tourniaire J, Mentha G et al. (1994) Enhancement of liver hemangiomas on T1-weighted MR SE images by superparamagnetic iron oxide particles. J Comput Assist Tomogr 18:888-896
30. Oudkerk M, van den Heuvel AG, Wielopolski PA, Schmitz PIM, Borel Rinkes IHM, Wiggers T (1997) Hepatic lesions: detection with ferum-oxide-enhanced T1-weighted MR imaging. Radiology 203:449-456
31. Muller RN (1995) Encyclopedia of nuclear magnetic resonance, pp 1438-1444
32. Mergo PJ, Helmberger T, Nicolas AI, Ros PR (1996) Ring enhancement in ultrasmall superparamagnetic iron oxide imaging: a potential new sign for characterization of liver lesions. Am J Roentgenol 166:379-384
33. Harisinghani MG, Saini S, Weissleder R et al. (1997) Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood-pool contrast agent code-7227. Radiology 202:687-691
34. Mergo PJ, Engelken JD, Helmberger T, Ros PR (1998) MRI in focal liver disease: a comparison of small and ultra-small superparamagnetic iron oxide as hepatic contrast agents. J Magn Reson Imaging 8:1073-1078
35. Allkemper T, Bremer C, Matuszewski L, Ebert W, Reimer P (2002) Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. Radiology 223:432-438
36. Prince M, Yacel EK, Kaufman JA, Harrison DC, Geller SC (1993) Dynamic gadolinium-enhanced 3DFT abdominal MR arteriography. J Magn Reson Imaging 3:877-881
37. Reimer P, Allkemper T, Matuszewski L, Balzer T (1999) Contrast-enhanced 3D-MRA of the upper abdomen with a bolus-injectable SPIO (SH U 555 A). J Magn Reson Imaging 10:65-71
38. Leung DA, McKinnon GC, Davis CP, Pfammatter T, Krestin GP, Debatin JF (1996) Breath-hold, contrast-enhanced, three-dimensional MR angiography. Radiology 200:569-571
39. Weissleder R, Bogdanov A, Neuwelt E, Papisov M (1995) Long-circulating iron oxides for MR imaging. In: Torchilin V et al. (ed) Advanced drug delivery reviews. CRC, Boca Raton, Florida, pp 321-334
40. Deckers F, Corthouts B, Nackaerts Y, Ozsarlak O, Parizel PM, De Schepper AM (1997) The influence of MR field strength on the detection of focal liver lesions with superparamagnetic iron oxide. Eur Radiol 7:887-892
41. Reimer P, Mueller M, Marx C, Balzer T (2002) Evaluation of the time-window for Resovist-enhanced T2-weighted MRI of the liver. Acad Radiol 9 (Suppl 2):336-338
42. Okon E, Pouliquen D, Okon P et al. (1994) Biodegradation of magnetite dextran nanoparticles in the rat: a histologic and biophysical study. Lab Invest 71:895-903
43. Frank H, Weissleder R, Brady TJ (1994) Enhancement of MR angiography with iron oxide: preliminary studies in whole-blood phantom and in animals. Am J Roentgenol 162:209-213
44. Blood CH, Zetter BR (1990) Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1032:89-118
45. Brasch R, Pham C, Shames D et al. (1997) Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 7:68-74
46. Brasch RC (1991) Rationale and applications for macromolecular Gd-based contrast agents. Magn Reson Med 22:282-287
47. Hulka C, Edmister WB, Smith BL et al. (1997) Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 205:837-842
48. Moore A, Weissleder R, Bogdanov A Jr (1997) Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 7:1140-1145